Clinical trial
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
NCT00239330 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00239330 |
|---|---|
| Title | Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy |
| Official title | An Open-label, Randomised, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesteremia |
| Intervention type | Drug |
| Interventions | Rosuvastatin, Atorvastatin |
| Enrollment | 824 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Oct 17, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Belgium |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: